Nanoformulated meloxicam and rifampin: inhibiting quorum sensing and biofilm formation in Pseudomonas aeruginosa.

Nanomedicine (London, England) Pub Date : 2024-03-01 Epub Date: 2024-02-13 DOI:10.2217/nnm-2023-0268

Malihe Khorramdel, Fatemeh Peyravii Ghadikolaii, Seyed Isaac Hashemy, Hossein Javid, Masoud Homayouni Tabrizi

{"title":"Nanoformulated meloxicam and rifampin: inhibiting quorum sensing and biofilm formation in Pseudomonas aeruginosa.","authors":"Malihe Khorramdel, Fatemeh Peyravii Ghadikolaii, Seyed Isaac Hashemy, Hossein Javid, Masoud Homayouni Tabrizi","doi":"10.2217/nnm-2023-0268","DOIUrl":null,"url":null,"abstract":"Background: We aimed to investigate the simultaneous effects of meloxicam and rifampin nanoformulations with solid lipid nanoparticle (SLN) and nanostructured lipid carrier (NLC) substrates on inhibiting the quorum-sensing system of Pseudomonas aeruginosa and preventing biofilm formation by this bacterium. Methods: Antimicrobial activity of rifampin and meloxicam encapsulated with SLNs and NLCs against P. aeruginosa PAO1 was assessed by disk diffusion, minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC). Results: The SLN formulation was associated with lower doses for the MIC and minimum bactericidal concentration in comparison to NLC. Moreover, our results demonstrated that both nanoformulations were able to produce 100% inhibition of the biofilm formation of P. aeruginosa PAO1. Conclusion: All these findings suggest that meloxicam and rifampin encapsulated with SLNs could be the most effective formulation against P. aeruginosa.","PeriodicalId":74240,"journal":{"name":"Nanomedicine (London, England)","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nanomedicine (London, England)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2217/nnm-2023-0268","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/2/13 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Background: We aimed to investigate the simultaneous effects of meloxicam and rifampin nanoformulations with solid lipid nanoparticle (SLN) and nanostructured lipid carrier (NLC) substrates on inhibiting the quorum-sensing system of Pseudomonas aeruginosa and preventing biofilm formation by this bacterium. Methods: Antimicrobial activity of rifampin and meloxicam encapsulated with SLNs and NLCs against P. aeruginosa PAO1 was assessed by disk diffusion, minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC). Results: The SLN formulation was associated with lower doses for the MIC and minimum bactericidal concentration in comparison to NLC. Moreover, our results demonstrated that both nanoformulations were able to produce 100% inhibition of the biofilm formation of P. aeruginosa PAO1. Conclusion: All these findings suggest that meloxicam and rifampin encapsulated with SLNs could be the most effective formulation against P. aeruginosa.

查看原文本刊更多论文

纳米配方美洛昔康和利福平：抑制铜绿假单胞菌的法定量感应和生物膜形成。

背景：我们旨在研究美洛昔康和利福平纳米制剂与固体脂质纳米颗粒（SLN）和纳米结构脂质载体（NLC）底物对抑制铜绿假单胞菌法定人数感应系统和防止该细菌形成生物膜的同时作用。方法通过磁盘扩散、最低抑菌浓度（MIC）和最低杀菌浓度（MBC）评估用 SLNs 和 NLCs 包封的利福平和美洛昔康对铜绿假单胞菌 PAO1 的抗菌活性。结果显示与 NLC 相比，SLN 制剂的 MIC 和最低杀菌浓度剂量较低。此外，我们的研究结果表明，两种纳米制剂都能 100% 地抑制铜绿假单胞菌 PAO1 的生物膜形成。结论所有这些研究结果表明，用 SLNs 封装的美洛昔康和利福平可能是对铜绿假单胞菌最有效的制剂。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Nanomedicine (London, England)

自引率

0.00%

发文量